AIM: To compare survival outcomes in patients with non-small cell lung cancer (NSCLC) treated with modern-era drugs (antifolates, antiangiogenics, tyrosine kinase and anaplastic lymphoma kinase inhibitors, immunotherapy) with treatment initiation in 2011-12 and 2015-16, respectively. PATIENTS AND METHODS: Prospective data from Czech TULUNG Registry (960 patients from 2011-12 and 512 patients from 2015-16) were analyzed. Kaplan-Meier analysis was used to estimate overall survival (OS) and progression-free survival (PFS); Cox proportional hazards model to assess factors associated with 2-year survival. RESULTS: Survival at 2 years was more frequent in cohort 2015-16 compared to cohort 2011-12 (43.2% vs. 24% for adenocarcinoma; p<0.001 and 28.7% vs. 11.8% for squamous-cell lung carcinoma; p=0.002). Assignment to cohort 2015-16 and treatment multilinearity (two or more lines in sequence) were associated with higher probability of 2-year survival (hazard ratio=0.666 and hazard ratio=0.597; p<0.001). Comparison of 2-year survivors from both cohorts showed no differences. CONCLUSION: Survival at 2 years probability in stage IIIB-IV NSCLC doubled between 2011-12 and 2015-16; advanced-stage NSCLC may be considered a chronic disease in a large proportion of patients.

2nd Faculty of Medicine Charles University Prague Prague Czech Republic

Department of Pneumology and Thoracic Surgery Bulovka Hospital Prague Czech Republic

Department of Pneumology University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Pneumology University Hospital Motol Prague Czech Republic

Department of Pneumology University Hospital Pilsen Pilsen Czech Republic

Department of Respiratory Diseases Prostejov Hospital Prostejov Czech Republic

Department of Respiratory Diseases University Hospital Brno Brno Czech Republic

Department of Respiratory Medicine Thomayer Hospital Prague Czech Republic

Department of Respiratory Medicine University Hospital Olomouc Olomouc Czech Republic

Faculty of Economics and Administration Masaryk University Brno Czech Republic

Faculty of Medicine Charles University Prague Hradec Kralove Czech Republic

Faculty of Medicine Charles University Prague Pilsen Czech Republic

Faculty of Medicine Masaryk University Brno Czech Republic

Institute of Biostatistics and Analyses Ltd Brno Czech Republic

Palacky University Olomouc Czech Republic

Zobrazit více v PubMed

Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005;172(5):523–529. PMID: 15961694. PubMed

Cancer Facts Sheets: Lung Cancer. Globocan Cancer Observatory, World Health Organisation. 2018. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf Last accessed: July 23rd, 2019.

Novotvary 2016, komplet (Cancer Incidence in the Czech Republic, 2016): Institute of Health Information and Statistics of the Czech Republic. 2016. Available at: http://www.uzis.cz/en/node/8139 Last accessed: August 18th, 2019.

Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: Striking a moving target. JCI Insight. 2018;3(15):120858. PMID: 30089719. DOI: 10.1172/jci.insight.120858. PubMed PMC

Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT. Updated efficacy and safety data and impact of the EML4–ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019;14(7):1233–1243. PMID: 30902613. DOI: 10.1016/j.jtho.2019.03.007. PubMed

Noncommunicable diseases. World Health Organisation. 2018. Available at: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases Last accessed: July 23rd, 2019.

Bernell S, Howard SW. Use your words carefully: What is a chronic disease. Front Public Health. 2016;4:159. PMID: 27532034. DOI: 10.3389/fpubh.2016.00159. PubMed PMC

Goldstraw P, Groome P, Sobin LH, Gospodarowicz MK, Wittekind C. Hoboken, New Jersey, Wiley-Blackwell. 2009. Lung and pleural tumours. In: Sobin LH, Gospodarowicz MK, Wittekind C (eds.): UICC TNM Classification of Malignant Tumours Seventh Edition. pp. 136–146.

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–3551. PMID: 18506025. DOI: 10.1200/JCO.2007.15.0375. PubMed

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–2550. PMID: 17167137. DOI: 10.1056/NEJMoa061884. PubMed

Reck M, Paz-Ares LG, de Marinis F, Molinier O, Sahoo TP, Laack E, John W, Zimmermann AH, Visseren-Grul C, Gridelli C. PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2014;2:205–213. PMID: 24419418. DOI: 10.1097/JTO.0000000000000076. PubMed PMC

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol. 2003;21(12):2237–2246. PMID: 12748244. DOI: 10.1200/JCO.2003.10.038. PubMed

Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22(6):1103–1109. PMID: 15020612. PubMed

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L, Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie, Associazione Italiana Oncologia Toracica Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246. PMID: 22285168. DOI: 10.1016/S1470-2045(11)70393-X. PubMed

Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib. Cancer Res Treat. 2019;51(2):502–509. PMID: 29898592. DOI: 10.4143/crt.2018.117. PubMed PMC

Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13(3):300–308. PMID: 22277837. DOI: 10.1016/S1470-2045(11)70385-0. PubMed

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, FLAURA Investigators Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. PMID: 29151359. DOI: 10.1056/NEJMoa1713137. PubMed

Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011–1019. PMID: 22954507. DOI: 10.1016/S1470-2045(12)70344-3. PubMed PMC

Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): Updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452–463. PMID: 26973324. DOI: 10.1016/S1470-2045(15)00614-2. PubMed PMC

Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(12):1683–1696. PMID: 27836716. DOI: 10.1016/S1470-2045(16)30392-8. PubMed

Khan M, Lin J, Liao G, Tian Y, Liang Y, Li R, Liu N, Yuan Y. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Medicine. 2018;97(33) PMID: 30113497. DOI: 10.1097/MD.0000000000011936. PubMed PMC

Giroux Leprieur E, Dumenil C, Julie C, Giraud V, Dumoulin J, Labrune S, Chinet T. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. Eur J Cancer. 2017;78:16–23. PMID: 28407528. DOI: 10.1016/j.ejca.2016.12.041. PubMed

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR, KEYNOTE-024 Investigators Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. PMID: 27718847. PubMed

Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10(1):19–28. PMID: 11180574. PubMed

Sanders SL, Bantum EO, Owen JE, Thornton AA, Stanton AL. Supportive care needs in patients with lung cancer. Psychooncology. 2010;19(5):480–489. PMID: 19434625. DOI: 10.1002/pon.1577. PubMed

Carlsen K, Jensen AB, Jacobsen E, Krasnik M, Johansen C. Psychosocial aspects of lung cancer. Lung Cancer. 2005;47(3):293–300. PMID: 15713512. PubMed

Pearman T. Psychosocial factors in lung cancer. J Psychosoc Oncol. 2008;26(1):69–80. PMID: 18077263. PubMed

Earle CC. Outcomes research in lung cancer. J Natl Cancer Inst Monogr. 2004;33:56–77. PMID: 15504920. PubMed

Gu X, Zhang Q, Chu YB, Zhao YY, Zhang YJ, Kuo D, Su B, Wu B. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung Cancer. 2019;127:84–89. PMID: 30642557. DOI: 10.1016/j.lungcan.2018.11.029. PubMed

Kimura M, Yasue F, Usami E, Kawachi S, Iwai M, Go M, Ikeda Y, Yoshimura T. Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Mol Clin Oncol. 2018;9(2):201–206. PMID: 30101022. DOI: 10.3892/mco.2018.1640. PubMed PMC

Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L. Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive non-small-cell lung cancer in the United States. Value Health. 2015;18(6):774–782. PMID: 26409604. DOI: 10.1016/j.jval.2015.04.008. PubMed

Driver and actionable mutations in younger patients with lung cancer - are we searching properly?

Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry